Literature DB >> 25511122

Methylphenidate and the risk of trauma.

Kenneth K C Man1, Esther W Chan1, David Coghill2, Ian Douglas3, Patrick Ip4, Ling-Pong Leung5, Matthew S H Tsui5, Wilfred H S Wong4, Ian C K Wong6.   

Abstract

BACKGROUND AND
OBJECTIVE: Children and adolescents with attention-deficit/hyperactivity disorder (ADHD) are prone to sustaining trauma that requires emergency department (ED) admission. Methylphenidate (MPH) can reduce ADHD symptoms and may thus theoretically reduce the risk of trauma-related ED admission, but previous studies do not make this association clear. This study examines this association.
METHODS: A total of 17 381 patients aged 6 to 19 years who received MPH prescriptions were identified by using the Clinical Data Analysis & Reporting System (2001-2013). Using a self-controlled case series study design, the relative incidence of trauma-related ED admissions was compared with periods of patient exposure and nonexposure to MPH.
RESULTS: Among 17 381 patients prescribed MPH, 4934 had at least 1 trauma-related ED admission. The rate of trauma-related ED admission was lower during exposed periods compared with nonexposed periods (incidence rate ratio [IRR]: 0.91 [95% confidence interval (CI): 0.86-0.97]). The findings were similar only when the incident trauma episode was assessed (IRR: 0.89 [95% CI: 0.82-0.96]). A similar protective association was found in both genders. In validation analysis using nontrauma-related ED admissions as a negative control outcome, no statistically significant association was found (IRR: 0.99 [95% CI: 0.95-1.02]). All sensitivity analyses demonstrated consistent results.
CONCLUSIONS: This study supports the hypothesis that MPH is associated with a reduced risk of trauma-related ED admission in children and adolescents. A similar protective association was found in both male and female patients. This protective association should be considered in clinical practice.
Copyright © 2015 by the American Academy of Pediatrics.

Entities:  

Keywords:  Hong Kong; attention-deficit/hyperactivity disorder; emergency department; self-controlled case series; trauma

Mesh:

Substances:

Year:  2014        PMID: 25511122     DOI: 10.1542/peds.2014-1738

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  38 in total

Review 1.  Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases.

Authors:  Zheng Chang; Laura Ghirardi; Patrick D Quinn; Philip Asherson; Brian M D'Onofrio; Henrik Larsson
Journal:  Biol Psychiatry       Date:  2019-04-17       Impact factor: 13.382

2.  Association of attention-deficit/hyperactivity disorder with gambling disorder.

Authors:  Wolfgang Retz; Jutta Ringling; Petra Retz-Junginger; Monika Vogelgesang; Michael Rösler
Journal:  J Neural Transm (Vienna)       Date:  2016-06-21       Impact factor: 3.575

3.  Effectiveness of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Physical Injuries: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Kenneth K C Man; Patrick Ip; Esther W Chan; Siew-Ling Law; Miriam T Y Leung; Evelyn X Y Ma; Wan-Ting Quek; Ian C K Wong
Journal:  CNS Drugs       Date:  2017-12       Impact factor: 5.749

4.  Mortality Risk Associated with Haloperidol Use Compared with Other Antipsychotics: An 11-Year Population-Based Propensity-Score-Matched Cohort Study.

Authors:  Kim S J Lao; Angel Y S Wong; Ian C K Wong; Frank M C Besag; W C Chang; Edwin H M Lee; Eric Y H Chen; Joseph E Blais; Esther W Chan
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

5.  ADHD Medication and Substance-Related Problems.

Authors:  Patrick D Quinn; Zheng Chang; Kwan Hur; Robert D Gibbons; Benjamin B Lahey; Martin E Rickert; Arvid Sjölander; Paul Lichtenstein; Henrik Larsson; Brian M D'Onofrio
Journal:  Am J Psychiatry       Date:  2017-06-29       Impact factor: 18.112

6.  Association of Risk of Suicide Attempts With Methylphenidate Treatment.

Authors:  Kenneth K C Man; David Coghill; Esther W Chan; Wallis C Y Lau; Chris Hollis; Elizabeth Liddle; Tobias Banaschewski; Suzanne McCarthy; Antje Neubert; Kapil Sayal; Patrick Ip; Martijn J Schuemie; Miriam C J M Sturkenboom; Edmund Sonuga-Barke; Jan Buitelaar; Sara Carucci; Alessandro Zuddas; Hanna Kovshoff; Peter Garas; Peter Nagy; Sarah K Inglis; Kerstin Konrad; Alexander Häge; Eric Rosenthal; Ian C K Wong
Journal:  JAMA Psychiatry       Date:  2017-10-01       Impact factor: 21.596

Review 7.  Attention-Deficit/Hyperactivity Disorder.

Authors:  Tobias Banaschewski; Katja Becker; Manfred Döpfner; Martin Holtmann; Michael Rösler; Marcel Romanos
Journal:  Dtsch Arztebl Int       Date:  2017-03-03       Impact factor: 5.594

8.  Attention-Deficit/Hyperactivity Disorder Medication and Unintentional Injuries in Children and Adolescents.

Authors:  Laura Ghirardi; Henrik Larsson; Zheng Chang; Qi Chen; Patrick D Quinn; Kwan Hur; Robert D Gibbons; Brian M D'Onofrio
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2019-07-11       Impact factor: 8.829

9.  Dosage of methylphenidate and traumatic brain injury in ADHD: a population-based study in Taiwan.

Authors:  Yin-To Liao; Yao-Hsu Yang; Ting-Yu Kuo; Hsin-Yi Liang; Kuo-You Huang; Tsu-Nai Wang; Yena Lee; Roger S McIntyre; Vincent Chin-Hung Chen
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-08-30       Impact factor: 4.785

Review 10.  ADHD in children and youth: Part 2-Treatment.

Authors:  Mark E Feldman; Alice Charach; Stacey A Bélanger
Journal:  Paediatr Child Health       Date:  2018-10-24       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.